Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
686.4 INR | +0.85% | +0.73% | +25.78% |
Apr. 25 | Jubilant Pharmova Subsidiary's Canadian Manufacturing Unit Gets Five Observations from US FDA | MT |
Apr. 17 | Jubilant Pharmova Unit Gets VAI Status for Roorkee, India Facility | MT |
Sales 2022 | 61.3B 735M | Sales 2023 | 62.82B 753M | Capitalization | 44.42B 533M |
---|---|---|---|---|---|
Net income 2022 | 4.14B 49.62M | Net income 2023 | -610M -7.31M | EV / Sales 2022 | 1.37 x |
Net Debt 2022 | 22.03B 264M | Net Debt 2023 | 26.44B 317M | EV / Sales 2023 | 1.13 x |
P/E ratio 2022 |
14.9
x | P/E ratio 2023 |
-72.8
x | Employees | 5,778 |
Yield 2022 |
1.29% | Yield 2023 |
1.79% | Free-Float | 36.33% |
1 day | +0.79% | ||
1 week | +0.73% | ||
Current month | +20.38% | ||
1 month | +19.40% | ||
3 months | +18.96% | ||
6 months | +79.99% | ||
Current year | +25.78% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 46 | 17-05-22 | |
Chief Executive Officer | 37 | 17-05-22 | |
Arvind Chokhany
DFI | Director of Finance/CFO | 52 | 21-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 67 | 81-12-31 | |
Chairman | 71 | 78-06-20 | |
Chief Executive Officer | 46 | 17-05-22 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 686.4 | +0.85% | 87 518 |
24-04-26 | 680.6 | +0.42% | 238,359 |
24-04-25 | 677.8 | -0.66% | 216,020 |
24-04-24 | 682.3 | -0.44% | 98,798 |
24-04-23 | 685.3 | +0.62% | 233,991 |
Delayed Quote NSE India S.E., April 29, 2024 at 04:14 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+25.83% | 661B | |
+26.84% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+14.02% | 231B | |
+4.80% | 200B | |
-9.45% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- JUBLPHARMA Stock
- JUBLPHARMA Stock